AcquisitionsMay 1, 2026, 04:08 PM
GridAI Technologies Corp. Acquires Grid AI Corp., Pivots to AI Data Centers
AI Summary
GridAI Technologies Corp., formerly Entero Therapeutics, Inc., completed the acquisition of Grid AI Corp. on September 30, 2025, and subsequently rebranded. This strategic move pivots the company's core focus to developing AI data center energy orchestration software solutions, while scaling back its legacy residential energy management platforms. Concurrently, the company divested its ImmunogenX biopharmaceutical business, offloading $9.3 million in secured debt. The company also addressed multiple Nasdaq compliance issues throughout 2025 and continues development of its Adrulipase program.
Key Highlights
- Acquired 100% of Grid AI Corp. on September 30, 2025, issuing 424,348 common shares and 38,801.546 Series H preferred shares.
- Changed name from Entero Therapeutics, Inc. to GridAI Technologies Corp. and ticker from ENTO to GRDX on December 1, 2025.
- Divested ImmunogenX, LLC on December 31, 2025, retaining $695,814 in payables and offloading $9.3 million in debt.
- Initiated strategic pivot to AI data center energy orchestration, scaling back legacy DLS and ALICE platforms.
- Effected a 1-for-3 reverse stock split on August 18, 2025, to regain Nasdaq minimum bid price compliance.
- Jason Sawyer became CEO in December 2025, alongside other board and management changes.
- Received Nasdaq notice on April 22, 2026, for failure to timely file its 2025 Form 10-K.